A precision medicine approach to treating chronic inflammatory disease

Current treatment of I&I diseases still relies on trial-and-error approaches that address advanced stages of clinically diagnosed disease. As a result, a large proportion of patients do not benefit from treatment and fail to achieve meaningful long-term clinical targets of low disease activity or remission.

ALLInBio is developing a precision immunology approach that allows the selection and early treatment of "at-risk" patient populations that are genetically predisposed to rapidly progress and develop severe disease. Through this approach, we will shift patient care in chronic inflammation from treating symptoms to addressing the root cause of disease.